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Abstract    41	  
Relapse  of  acute   lymphoblastic   leukemia  (ALL)  may  occur   in  extramedullary  sites,  mainly  central  42	  
nervous  system  (CNS)  and   testis.  Optimal  post-­remissional   treatment   for   isolated  extramedullary  43	  
relapse  (IEMR)  is  still  controversial.  We  collected  data  of  children  treated  with  hematopoietic  stem  44	  
cell  transplantation  (HSCT)  for  ALL  IEMR  from  1990  to  2015  in  Italy.  Among  281  patients,  167  had  45	  
a  relapse  confined  to  CNS,  73  to  testis,  14  to  mediastinum,  27  to  other  organs.  Ninety-­seven  patients  46	  
underwent  autologous  HSCT,  79  received  allogeneic  HSCT  from  a  matched  family  donor,  75  from  a  47	  
matched  unrelated  donor  and  30  from  an  HLA-­haploidentical  donor.  The  10-­year  overall  survival  was  48	  
56%  and  was  not  influenced  by  gender,  ALL  blast  immune-­phenotype,  age,  site  of  relapse,  duration  49	  
of   first   remission   and   type   of   HSCT.   In   multivariable   analysis,   the   only   prognostic   factors   were  50	  
disease  status  at  HSCT  and  year  of   transplantation.  Patients   transplanted   in   third  or  subsequent  51	  
complete  remission  (CR)  had  a  risk  of  death  2.3  times  greater  than  those  in  CR2.  Children  treated  52	  
after  2000  had  half  the  risk  of  death  than  those  treated  before  that  year.  	  53	  
Our  results  suggest  that  both  autologous  and  allogeneic  HSCT  may  be  considered  for  treatment  of  54	  
pediatric  ALL  IEMR  after  the  achievement  of  CR2.  	  55	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Introduction  	  58	  
Although  current   treatment  protocols  cure  up   to  85%  of  children  affected  by  acute   lymphoblastic  59	  
leukemia  (ALL),   relapse   is  still   the   leading  cause  of   treatment   failure,  affecting  approximately  15-­60	  
20%  of  patients.  Leukemia  relapse  may  occur  in  extramedullary  sites,  mainly  central  nervous  system  61	  
(CNS)  and  testis,  either  alone  or  in  combination  with  bone  marrow  (BM)  relapse  [1].	  62	  
Site  of  relapse  and  duration  of  first  remission  are  the  most  important  prognostic  factors  in  relapsed  63	  
ALL,   early   and   isolated   BM   relapse   predicting   the   worst   outcome   [2,   3].   While   the   benefit   of  64	  
allogeneic  hematopoietic  stem  cell  transplantation  (allo-­HSCT)  has  been  demonstrated  for  high-­risk  65	  
relapsed  patients,  optimal  post-­remissional  treatment  for  low-­risk  patients  is  still  controversial  [4-­8].  66	  
Our   previous   studies   [9,   10]   demonstrated   that   autologous   HSCT   (auto-­HSCT)  may   be   a   good  67	  
curative  option  for  children  experiencing  isolated  extramedullary  relapse  (IEMR).  The  observation  68	  
that  the  immune-­surveillance  exerted  by  the  allograft  against  leukemia  (graft-­versus  leukemia,  GVL,  69	  
effect)   is  more  effective   in  preventing  BM  relapse   than   IEMR  [11],   led  us   to  hypothesize   that   the  70	  
agents  used  in  the  conditioning  regimen  (including  total  body  irradiation,  TBI)  may  be  sufficient  for  71	  
disease  control  in  patients  with  IEMR.  This  approach  may  reduce  the  toxicity  associated  with  allo-­72	  
HSCT  and  largely  related  to  graft-­versus-­host  disease  (GVHD)  occurrence.	  73	  
Therefore,   to   further  address   the   role  of  auto-­  and  allo-­HSCT   in  patients  experiencing   IEMR,  we  74	  
analyzed  data  of  a   large  cohort  of  children  with  first  or  subsequent  ALL  IEMR  treated  with  HSCT  75	  
over  a  25-­year  period  in  Italy.  To  the  best  of  our  knowledge,  this  is  the  largest  study  that  uniformly  76	  
analyzes  the  outcome  of  this  subgroup  of  patients.	  77	  
  78	  
Patients  and  Methods  	  79	  
This  is  a  retrospective  multicenter  study  involving  20  Italian  centers  affiliated  to  the  Italian  Pediatric  80	  
Onco-­Hematology  Association  (AIEOP)  network.	  81	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Data  were  extracted  from  the  AIEOP-­Stem  Cell  Transplantation  (AIEOP-­SCT)  Registry.  We  included  82	  
children  (age  1-­18  years)  with  ALL  IEMR  who  underwent  HSCT  between  1st  of  January  1990  and  83	  
31st  of  December  2015.  Follow  up  was  updated  on  January  30th,  2018.  	  84	  
Written  informed  consent  was  obtained  from  parents  or  legal  guardians.  	  85	  
IEMR  was  defined  as  the  presence  of  lymphoblasts  in  extramedullary  sites  with  less  than  5%  blasts  86	  
in  BM.  CNS  relapse  was  defined  as  the  presence  of  >5  cell/µL  in  the  cerebrospinal  fluid  (CSF)  and  87	  
detection  of  lymphoblasts  by  CSF  cytomorphology,  or  alternatively,  by  clinical  or  radiological  signs.  88	  
Relapse  involving  testis  or  other  organs  was  confirmed  by  biopsy.	  89	  
“Very  early”  relapse  was  defined  when  disease  recurred  less  than  18  months  from  primary  diagnosis,  90	  
“early”  when  disease  recurred   later   than  18  months   from  diagnosis  and   less   than  6  months   from  91	  
treatment  discontinuation,  and   “late”  when  disease   recurred  more   than  6  months   from   treatment  92	  
discontinuation  [3].	  93	  
At  diagnosis  and  relapse,  patients  were  treated  according  to  the  national  protocols  available  at  that  94	  
time,  mainly  based  on  Berlin-­Frankfurt-­Münster  (BFM)  Study  Group  backbone.  	  95	  
HSCT  was  performed  in  patients  with  second  or  subsequent  complete  remission  (CR),  or,  in  a  limited  96	  
number  of  cases,  with  active  disease.  If  an  HLA-­matched  family  donor  (MFD)  was  available,  allo-­97	  
HSCT   was   performed.   If   not,   auto-­HSCT,   HSCT   from   a   matched   unrelated   donor   (MUD)   or  98	  
haploidentical  (haplo-­HSCT)  were  considered.  This  decision  was  taken  by  the  single  center.	  99	  
Statistical  analysis	  100	  
Overall  Survival  (OS)  was  defined  as  the  time  from  transplantation  to  either  last  follow-­up  or  death  101	  
due  to  any  cause,  whereas  disease-­free  survival  (DFS)  as  the  time  elapsing  from  transplantation  to  102	  
either   last   follow-­up   or   disease   recurrence   or   death   due   to   any   cause,  whichever   occurred   first.  103	  
Relapse-­free  survival  (RFS)  was  defined  as  the  time  from  transplantation  to  documented  relapse  of  104	  
ALL.  Cumulative  incidence  (CI)  of  treatment-­related  mortality  (TRM)  was  defined  as  the  time  from  105	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transplantation  to  death  from  causes  other  than  disease  recurrence/progression,  considering  relapse  106	  
as  the  competing  event.	  	  107	  
OS,  DFS,  and  RFS  were  calculated  at  10  years  using  the  Kaplan-­Meier  method;;  difference  in  survival  108	  
between  groups  was  estimated  through  the  log-­rank  test.  	  109	  
Cumulative   incidence   of   TRM  was   evaluated   at   100   days,   6  months,   1   year   and   10   years   after  110	  
transplantation.   Incidence   curves   were   compared   using   the   Gray’s   test.   In   multivariable   Cox  111	  
regression  analysis,  all  factors  with  a  p-­value  <0.2  in  univariable  analysis  were  included.  The  risk  of  112	  
death  was   expressed   as   the   hazard   ratio   (HR)  with   95%   confidence   interval.   Differences   in   the  113	  
distribution   of   various   parameters   were   compared   using   Chi-­square   or   Fisher   exact   test   as  114	  
appropriate.  A  p-­value  <0.05  was  considered  statistically  significant.	  115	  




Results  	  118	  
Patient  characteristics	  119	  
Two  hundred  and  ninety-­two  children  with  IEMR  of  ALL  underwent  HSCT  from  1990  to  2015  in  Italy.  120	  
Patients   included   in   the  study  were  281;;  11  children  were  excluded  because  of   insufficient  data.  121	  
Patients’  characteristics  are  detailed  in  Table  1,  while  conditioning  regimens  are  listed  in  Table  2.    122	  
Mean  follow-­up  from  transplantation  was  6.9  years  (median  4.4  years,  range  0.03-­25.8  years).    123	  
Outcome  124	  
Eighty-­three  out  of  281  patients  (29.5%)  experienced  a  second  relapse  or  disease  progression  at  a  125	  
median  time  of  176  days  (range  15-­2345)  from  HSCT:  49  patients  had  an  isolated  BM  recurrence,  126	  
16  an  IEMR  and  7  children  experienced  a  combined  relapse.  The  site  of  recurrence  was  unknown  127	  
in  11  patients.  One  hundred  and  eighteen  patients  (42.0%)  died  at  a  median  time  of  219  days  (range  128	  
12-­6623)   from  HSCT:      63   from   relapse,   46   from   treatment-­related   complications   (14/46  were   in  129	  
relapse),   4   from  a   second   tumor,   5   from  an   unknown   event.  Grade   II-­IV   acute  GVHD   (aGVHD)  130	  
occurred  in  79  of  184  patients  (42.9%)  who  received  an  allograft,  while  chronic  GVHD  (cGVHD)  was  131	  
diagnosed  in  32  out  of  151  patients  (21.2%)  alive  at  day  +100  after  allo-­HSCT.    132	  
Overall  survival	  133	  
The  OS  for  the  entire  cohort  was  56%±3%  at  10  years;;  it  was  not  influenced  by  gender,  ALL  blast  134	  
immune-­phenotype   (B-­cell   precursor   [Bcp]-­ALL  vs  T-­ALL),  age   (≤10  years  vs   >10  years),   site  of  135	  
relapse,  source  of  stem  cells,  use  of  TBI  during  the  conditioning  regimen  and  length  of  first  CR  (10-­136	  
year  OS   for  very  early,  early  and   late   IEMR  was  52%±6%,  53%±5%,  and  61%±6%  respectively,  137	  
p=0.39).   No   statistically   significant   difference   was   also   observed   if   different   type   of   HSCT  were  138	  
compared:  OS  for  auto-­HSCT,  MFD,  MUD  and  haplo-­HSCT  was  57%±5%,  56%±6%,  62%±6%  and  139	  
46%±10%,  respectively,  p=0.09  (Figure  1).    140	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In   univariable   analysis,   the   prognostic   factors   associated   with   OS   were:   remission   status   at  141	  
transplantation  and   the   year   in  which  patients  were   treated.  Patients   transplanted   in  CR2  had  a  142	  
better  OS  at  10  years  (64%±4%),  in  comparison  to  both  those  transplanted  in  subsequent  CR  (CR>2)  143	  
who  showed  an  OS  of  44%±7%  and  patients  transplanted  with  active  disease  who  had  an  OS  of  144	  
11%±7%   (p<0.0001)   (Figure   2).   For   patients   given   HSCT   before   2000,   the   10-­year   OS   was  145	  
45%±5%,  while  that  of  children  transplanted  after  2000  was  63%±4%  (p=0.0009).    	  146	  
Disease-­free  survival  	  147	  
The  10-­year  DFS  for  the  whole  cohort  was  54%±3%.  Like  OS,  DFS  did  not  differ  in  relation  to  gender,  148	  
ALL  blast  immune-­phenotype,  age,  duration  of  first  CR,  type  of  HSCT  or  stem  cell  source.  As  for  site  149	  
of  relapse,  DFS  was  slightly  better  for  patients  with  isolated  testicular  relapse  (65%±6%)  compared  150	  
to  CNS  relapse  (49%±4%),  CNS  relapse  together  with  other  sites  (55%±15%),  mediastinal  relapse  151	  
(40%±14%)   and   other   sites   involvement   (65%±13%),   but   this   difference   was   not   statistically  152	  
significant  (p=0.22).  	  153	  
Factors   influencing  DFS  were:   presence   of   TBI   in   the   conditioning   regimen,   remission   status   at  154	  
HSCT  and  year  of  transplantation.  TBI-­containing  regimens  were  associated  with  a  better  DFS  at  10  155	  
years  compared  to  non-­TBI  containing  regimens  (58%±4%  vs  37%±8%,  p=0.008).  Remission  status  156	  
at   HSCT   strongly   correlated   with   DFS:   patients   transplanted   in   CR2   had   a   better   10-­year   DFS  157	  
(63%±4%)  in  comparison  to  those  transplanted  in  CR>2  (39%±7%)  or  not  in  remission  (11%±7%)  158	  
(p<0.0001).  DFS  for  patients  transplanted  either  before  or  after  2000  was  45%±5%  and  61%±4%,  159	  
respectively  (p=0.0008).    160	  
Transplant-­Related  Mortality	  161	  
TRM  for   the  entire  cohort  was  10%±2%  at  100  days,  11%±2%  both  at  6  months  and  1  year  and  162	  
16%±2%  at  10  years.  TRM  for  auto-­HSCT  was  4%±2%,  6%±2%,  6%±2%,  and  11%±3%,  while  TRM  163	  
for  allo-­HSCT  (MUD,  MFD  and  haplo-­HSCT)  was  13%±2%,  14%±3%,  14%±3%,  and  18%±3%  at  164	  
9	  
	  
100   days,   6   months,   1   year   and   10   years,   respectively.   Comparison   resulted   not   statistically  165	  
significant  (p=0.08).	  166	  
No  statistical  significant  difference  was  observed  if  TRM  of  patients  transplanted  before  2000  was  167	  
compared  to  that  of  patients  transplanted  after  2000  (p=0.33).  In  detail,  TRM  of  patients  transplanted  168	  
before  2000  was  15%±3%,  16%±4%,  17%±3%,  and  17%±4%  at  100  days,  6  months,  1  year  and  10  169	  
years,   respectively.  TRM  of  patients   transplanted  after  2000  was  6%±2%,  8%±2%,  8%±2%,  and  170	  
15%±3%  at  100  days,  6  months,  1  year  and  10  years,  respectively.  	  171	  
Subgroup  analysis  and  multivariable  analysis	  172	  
As  length  of  first  CR  is  one  of  the  most  important  prognostic  factors  in  relapsed  ALL,  we  performed  173	  
separate  analyses  for  patients  with  very  early,  early  and  late  IEMR.  	  Regarding  patients  experiencing  174	  
very  early   relapse  (n=87),  DFS  and  OS  at  10  years  showed  a   trend   in   favor  of  allogeneic  HSCT  175	  
(MFD,  MUD  and  haplo  combined)  versus  autologous  HSCT  (58%±6%  vs  44%±12%  and  59%±6%  176	  
vs  44%±12%,  p=0.28  and  0.29  respectively)  (Figure  3A).  In  early  relapsed  patients  (n=97),  DFS  and  177	  
OS  at  10  years  were  comparable   irrespectively  whether  patients  were   treated  with  either  allo-­  or  178	  
auto-­HSCT   (50±7%  vs   55%±9%,  p=0.88  and  52%±7%  vs   54%±9%,  p=0.87)   (Figure  3B).   In   late  179	  
relapses  (n=87),  DFS  and  OS  at  10  years  were  slightly  better  with  auto-­HSCT  than  with  allo-­HSCT:  180	  
65%±8%  vs  48%±9%  and  68%±7%  vs  52%±9%,  respectively  (Figure  3C).  However,  the  difference  181	  
was  not  statistically  significant  (p=0.13  and  p=0.12).	  182	  
Remission   status   at   transplantation   is   well   known   to   influence   outcome;;   thus,   we   conducted   a  183	  
separate  analysis  for  patients  in  CR2  at  time  of  HSCT  (n=204).  RFS  and  OS  for  this  cohort  were  184	  
74%±3%   and   64%±3%,   respectively;;   outcome   of   patients   given   either   autologous   or   allogeneic  185	  
HSCT  was  similar.  Ten-­year  RFS  of  patients   transplanted   in  CR2  after   year  2000  was  better  as  186	  
compared  to  that  of  patients  transplanted  before  2000  (79%±4%  vs  64%±6%,  respectively,  p=0.009).    187	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Since  TBI   is   regarded  as   the  standard   regimen  conditioning   in  ALL,  we  analyzed  separately   the  188	  
group  of  patients  who  received  TBI:  10  year-­DFS  did  not  differ  regarding  the  type  of  transplant  (auto  189	  
vs  allo:  61%±5%  vs  58%±4%,  p=0.67).  190	  
A  separate  analysis  on  patients   transplanted   in  more  recent  years   (from  2000   to  2015)  was  also  191	  
performed.  Results  confirmed  what  we  observed  analyzing  the  whole  cohort  of  patients:  10-­year  OS  192	  
and  DFS  were  not  influenced  by  site  of  relapse,  presence  of  TBI,  time  of  relapse  and  type  of  HSCT.  193	  
Ten-­year   OS   for   auto,   MFD,   MUD   and   haplo-­HSCT   were   71%±7%,   63%±9%,   66%±6%   and  194	  
46%±13%  (p=0.18).  Remission  status  at   transplantation  was,  again,   the  only  variable   influencing  195	  
outcome:  OS  was  71%±4%  for  patients  in  CR2,  46%±9%  for  those  in  CR>2  (p<0.0001);;  DFS  was  196	  
69%±4%  and  45%±9%(p<0.0001),  respectively.    197	  
For   patients   treated   with   allo-­HSCT,   occurrence   of   aGVHD   was   associated   with   a   better   DFS  198	  
(74%±6%  vs  48%±7%,  p=0.0008)  and  a  better  OS  (63%±5%  vs  46%±7%,  p=0.028).  Considering  199	  
only  patients  given  an  allograft  in  CR,  occurrence  of  aGVHD  conferred  a  better  RFS:  76%±5%  vs  200	  
58%±6%,  p=0.009.  Bone  marrow  RFS  was  87%±4%  for  patients  who  did  experience  aGVHD  versus  201	  
74%±6%   for   those   who   did   not   (p=0.02);;   conversely,   extra-­medullary   RFS   was   not   affected   by  202	  
aGVHD  occurrence  (90%±4%  vs  89%±5%,  p=0.79).  Presence  of  cGVHD  did  not  influence  patients’  203	  
outcome  (data  not  shown).  204	  
Multivariable   analysis   was   conducted   after   adjustment   for   remission   status:   patients   with   active  205	  
disease  at  transplantation  were  excluded  due  to  the  high  incidence  of  treatment  failure  in  this  group.  206	  
As  shown  in  Table  3,  in  multivariable  analysis  the  only  factors  influencing  OS  in  patients  with  IEMR  207	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  210	  
Although  the  vast  majority  of  children  affected  by  ALL  are  cured  with  current  protocols,  relapses  still  211	  
occur  and  pose  remarkable  challenges  to  pediatric  hematologists.  Allo-­HSCT  is  currently  used  to  212	  
treat  patients  in  CR2  with  high-­risk  features  (very  early/early  and  isolated  BM  relapse,  recurrence  of  213	  
T-­lineage  ALL  [1,12]),  and  it  is  now  considered  the  standard  of  care  also  for  low-­risk  patients  who  214	  
present  minimal  residual  disease  (MRD)  positivity  at  the  end  of  induction  therapy  [13,14].  Treatment  215	  
of  extramedullary  relapse  is  less  well  established.  The  absence  of  BM  involvement  is  traditionally  216	  
considered  a  favorable  prognostic  feature  [15],  and  patients  with  isolated  CNS  (ICNS)  relapse  are  217	  
treated  with  intensive  systemic  and  intrathecal  chemotherapy  (CT),  followed  by  either  cranio-­spinal  218	  
or  cranial  radiotherapy  (RT)  [5,  7,  16,  17].  EFS  with  this  approach  ranges  from  45%  [3,  7,  18,  19]  to  219	  
70%  [16].  Despite  the  high  cure  rate  obtained  in  two  Children  Oncology  Group  trials  [16,  20],  with  220	  
global   5-­year   EFS   approaching   70%,   for   particular   subgroups   of   IEMR   prognosis   is   still   dismal.  221	  
Patients  experiencing  very  early  and  early  IEMR  or  ICNS  relapses  have  a  survival  probability  of  only  222	  
20-­30%  in  most  studies  [3,  7,  18,  19].  HSCT  has  been  used  for  treatment  of  IEMR,  but  published  223	  
data  are  conflicting  and  limited  to  small  numbers  of  patients  [6,  21-­23].  Our  previous  work  [9]  showed  224	  
that  EFS  of  children  with  early  IEMR  treated  with  auto-­HSCT  was  clearly  superior  to  that  of  patients  225	  
who  received  CT/RT  (56%  vs  12%).  Moreover,  in  another  report,  we  demonstrated  that  auto-­HSCT  226	  
offers   a   better   chance   of   cure   patients   in  CR2   than   in   subsequent  CR  [10].  More   recent   papers  227	  
reported  comparable  outcome  in  patients  with  ICNS  relapse  in  CR2  treated  with  allo-­HSCT  or  CT/RT  228	  
[2,  5,  7].  	  229	  
In  this  study,  we  present  the  largest  cohort  of  patients  with  morphologically  defined  IEMR  of  ALL  and  230	  
the  largest  number  of  HSCT  ever  performed  for  this  indication,  with  a  long  follow-­up  (up  to  26  years  231	  
from  HSCT).  In  our  cohort,  10-­year  OS  and  DFS  were  around  60%  with  eiher  autologous,  MFD  and  232	  
MUD-­HSCT.  Even  if  a  control  group  of  patients  treated  with  CT/RT  was  not  included  in  this  study,  233	  
our  results  are  comparable  with  the  literature,  as  reported  OS  with  CT/RT  is  45-­70%  [3,  5,  7,  16-­18,  234	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20].  Moreover,  if  only  patients  transplanted  in  CR2  were  considered,  as  in  other  published  series,  235	  
the  10-­year  OS  of  64%  is  in  line  with  the  most  favorable  reports  [16,  20].  	  236	  
Interestingly,   in   our   study,   the   use   of   HSCT   seems   to   abrogate   the   impact   of   some   “classical”  237	  
prognostic  factors,  like  site  of  relapse,  duration  of  first  remission  and  ALL  blast  immune-­phenotype.  238	  
Similar  results  were  found  in  the  whole  cohort,  as  well  as  in  the  group  of  patients  treated  in  more  239	  
recent  years  (from  2000  to  2015).  The  only  factors  influencing  outcome  resulted  to  be  year  of  HSCT  240	  
and   remission   status   at   transplantation.   Taking   into   account   the   prognostic   impact   of   year   of  241	  
transplantation,   this   may   reflect   improvement   in   patient   selection:   the   10-­year   RFS   for   patients  242	  
transplanted  before  2000  was  better  than  that  of  patients  transplanted  after  2000;;  on  the  contrary,  243	  
10-­year  TRM  pre  and  post-­2000  did  not  differ.  There  is  the  possibility  that  MRD  assessment  during  244	  
therapy  guided  decisions  on  CT  administration,  time  and  type  of  HSCT  in  single  centers.  As  far  as  245	  
the  prognostic  significance  of  remission  status  before  HSCT  is  concerned,  these  data  confirm  what  246	  
we  reported  previously  [10],  namely  that  outcome  is  significantly  better  for  children  transplanted  in  247	  
CR2  than  in  subsequent  remission.  This  observation  emphasizes  the  importance  of  identifying  those  248	  
patients  at  higher  risk  of  further  relapse,  who,  thus,  may  benefit  of  HSCT  soon  after  the  achievement  249	  
of  CR2.  Very  early  and  early  IEMR  or  ICNS  relapses  treated  with  CT/RT  have  been  previously  shown  250	  
to  have  a  survival  probability  around  20-­30%  [3,  7,  18,  19].  The  use  of  HSCT  in  our  study  improved  251	  
the  OS  to  53%  for  early  relapses  and  52%  for  very  early  relapses.  This  result  is  even  more  relevant  252	  
considering  that  patients  with  third  or  subsequent  CR  and  even  with  active  disease  at  time  of  HSCT  253	  
were  included  in  this  analysis.  Based  on  these  data,  we  suggest  considering  HSCT  for  patients  with  254	  
very  early/early  IEMR  once  that  the  CR  is  achieved.  255	  
Furthermore,  no  difference  in  outcome  was  observed  regarding  the  type  of  HSCT.  This  finding  is  in  256	  
line   with   our   previous   study,   where   we   reported   that   auto-­HSCT   had   the   same   chance   to   cure  257	  
children  with  ICNS  relapse  than  MFD-­HSCT  [9].  Present  data  strengthen  this  observation,  including  258	  
MUD-­HSCT  and  (although  with  a  low  number  of  cases)  haplo-­HSCT.  The  favorable  results  obtained  259	  
with  either  auto  and  allo-­HSCT  may  be  due   to   the   large  use  of  TBI   in   the  conditioning   regimen.  260	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Moreover,  based  on  published  reports  [11,  24,  25],  we  speculate  that  the  GVL  effect  of  allo-­HSCT  261	  
may  be  less  relevant  in  extramedullary  site,  as  migration/homing  of  donor  T  cells  may  be  impaired  262	  
at  extramedullary  sites.  In  this  regard,  it  was  reported  that  donor  cells  are  absent  in  extra-­medullary  263	  
sites  of  patients  who   relapsed  after  HSCT   [26,27].  Furthermore,  donor   lymphocytes   infusion  and  264	  
recent  chimeric  antigen  receptor  T  cells  have  been  reported  to  be  less  effective  in  extramedullary  265	  
disease  control  [28-­30].  In  line  with  these  observations  and  with  a  previous  report  [11],  in  our  allo-­266	  
HSCT  cohort,  occurrence  of  aGVHD  decreased  the  incidence  of  subsequent  BM  relapses  but  no  of  267	  
subsequent  IEMR.    Therefore,  we  can  hypothesize  that,  in  the  group  of  patients  with  IEMR  of  ALL,  268	  
those  with  higher  risk  of  subsequent  BM  relapse  (i.e.,  children  with  positive  BM  MRD)  may  benefit  269	  
more   from   allo-­HSCT,  while   patients  with   pure   IEMR   relapse   (i.e.,   negative  BM  MRD)   could   be  270	  
offered  auto-­HSCT.    271	  
This  study  shows   that  both  auto-­  and  allo-­HSCT  are  effective   treatments   for   IEMR  of  ALL,   to  be  272	  
considered  as  soon  as  CR2  is  achieved.  Patients  with  late  IEMR,  currently  treated  with  CT/RT,  may  273	  
benefit  from  auto-­HSCT  also  in  terms  of  shorter  treatment  duration,  resulting  into  better  quality  of  life  274	  
for  patients  and  their  families.  Current  Italian  strategy  to  treat  children  with  very  early  and  early  IEMR  275	  
recommend   allo-­HSCT   [13].   This   study   shows   that   auto-­HSCT   may   be   a   good   alternative,  276	  
significantly  reducing  the  time  patients  wait  before  transplantation  and  the  risk  of  both  GVHD  and  277	  
infection-­related  mortality/morbidity  associated  with  allo-­HSCT.  The  role  of  auto-­HSCT  for  patients  278	  
with  late  IEMR  or  very  early/early  IEM  with  negative  BM  MRD  remains  to  be  assessed  in  future  trials.      279	  
The   retrospective   nature   of   this   study   and   the   absence   of   data   regarding   BM   MRD   before  280	  
transplantation  represent  significant  limitations  of  our  study;;  however,  the  large  number  of  patients  281	  
with   IEMR  and   the   long   follow-­up  strengthen  our   results.  The   role  of  auto-­  and  allo-­HSCT   in   the  282	  
treatment  of  IEMR  of  pediatric  ALL  should  be  further  explored  in  prospective  studies  including  MRD  283	  
assessment  for  stratifying  patients.  284	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total  (n=281)	   p  value	  
Gender	     	     	     	     	     	   0.83	  
Male	   67  (69.1%)	   58  (73.4%)	   55  (73.3%)	   23  (76.7%)	   203  (72.3%)	     
Female	   30  (30.9%)	   21  (26.6%)	   20  (26.7%)	   7  (23.3%)	   78  (27.7%)	     
Median  age  at  relapse,  years  
(range)	  
4.9  (0.3-­15.2)	   5.6  (1.0-­17.8)	   5.3  (0.4-­18.0)	   5.8  (1.5-­11.5)	      0.55	  
Blast  immune-­phenotype  #	     	     	     	     	     	   0.003*	  
Bcp	   82  (84.5%)	   59  (74.7%)	   55  (73.3%)	   15  (50.0%)	   211  (75.1%)	     
T	   7  (7.2%)	   10  (12.6%)	   15  (20.0%)	   9  (30.0%)	   41  (14.6%)	     
Other	   2  (2.1%)	   1  (1.3%)	   0	   0	   3  (1.1%)	     
Not  known	   6  (6.2%)	   9  (11.4%)	   5  (6.7%)	   6  (20.0%)	   26  (9.2%)	     
Site  of  relapse  #	     	     	     	     	     	   0.23	  
CNS	   57  (58.8%)	   51  (64.5%)	   44  (58.7%)	   15  (50.0%)	   167  (59.4%)	     
Testis	   34  (35.0%)	   17  (21.5%)	   14  (18.7%)	   8  (26.7%)	   73  (26.0%)	     
Mediastinum	   1  (1.0%)	   2  (2.6%)	   8  (10.7%)	   3  (10.0%)	   14  (5.0%)	     
CNS+other	   2  (2.1%)	   3  (3.8%)	   5  (6.6%)	   1  (3.3%)	   11  (3.9%)	     
CNS+  cerebral  parenchima	   1	   0	   2	   1	   4	     
CNS+testis	   0	   2	   1	   0	   3	     
CNS+mediastinum	   0	   0	   2	   0	   2	     
CNS+eye	   1	   1	   0	   0	   2	     
Other	   3  (3.1%)	   6  (7.6%)	   4  (5.3%)	   3  (10.0%)	   16  (5.7%)	     
Eye	   0	   3	   0	   1	   4	     
Lymph-­nodes	   1	   1	   0	   1	   3	     
Other  sites  (liver,  ovary,  kidney,  skin..)	   2	   2	   4	   1	   9	     
Time  to  relapse  #	     	     	     	     	     	   0.004*	  
Very  early	   16  (16.5%)	   27  (34.2%)	   33  (44.0%)	   11  (36.7%)	   87  (31.0%)	     
Early	   33  (34.0%)	   28  (35.4%)	   26  (34.7%)	   10  (33.3%)	   97  (34.5%)	     
Late	   42  (43.3%)	   21  (26.6%)	   16  (21.3%)	   8  (26.7%)	   87  (31.0%)	     
not  known	   6  (6.2%)	   3  (3.8%)	   0	   1  (3.3%)	   10  (3.5%)	     
Remission  status  at  HSCT	     	     	     	     	     	   0.003*	  
CR2	   78  (80.4%)	   58  (73.4%)	   56  (74.7%)	   12  (40.0%)	   204  (72.6%)	     
CR>2	   13  (13.4%)	   16  (20.3%)	   15  (20.0%)	   15  (50.0%)	   59  (21.0%)	     
Active  disease	   6  (6.2%)	   5  (6.3%)	   4  (5.3%)	   3  (10.0%)	   18  (6.4%)	     
TBI-­based  conditioning  #	     	     	     	     	     	   0.056	  
Yes	   82  (84.5%)	   71  (89.9%)	   55  (73.3%)	   27  (90.0%)	   235  (83.6%)	     
No	   14  (14.5%)	   7  (8.9%)	   18  (24.0%)	   3  (10.0%)	   42  (15.0%)	     
not  known	   1  (1.0%)	   1  (1.2%)	   2  (2.7%)	   0	   4  (1.4%)	     
Stem  cell  source  #	     	     	     	     	     	   <0.0001*	  
BM	   60  (61.9%)	   71  (89.9%)	   52  (69.4%)	   7  (23.3%)	   190  (67.6%)	     
CB	   0	   2  (2.5%)	   17  (22.6%)	   1  (3.3%)	   20  (7.1%)	     
PBSC	   36  (37.1%)	   3  (3.8%)	   6  (8.0%)	   22  (73.4%)	   67  (23.9%)	     
BM+other	   1  (1.0%)	   3  (3.8%)	   0	   0	   1  (0.4%)	     
Year  of  HSCT	     	     	     	     	     	   <0.0001*	  
1990-­2000	   57  (58.8%)	   37  (46.8%)	   7  (9.3%)	   6  (20%)	   107  (38.1%)	     
2000-­2015	   40  (41.2%)	   42  (53.2%)	   68  (90.7%)	   24  (80%)	   174  (61.9%)	     
	  
Table  1:  Characteristics  of  281  children  who  underwent  HSCT  for  isolated  extramedullary  relapse  
of  ALL  from  1990  to  2015  in  Italy.    
*  statistically  significant  (p<0.05).  #  analysis  of  significance  was  performed  among  most  representative  groups:  
immune-­phenotype  (T  vs  Bcp),  site  of  relapse  (CNS  vs  testis),  time  to  relapse  (very  early  vs  early  and  late),  
TBI-­based  conditioning  (Yes  vs  No),  stem  cell  source  (BM  vs  CB  vs  PBSC).	  
Abbreviations:  auto  autologous,  Bcp  B  cell  precursor,  BM  bone  marrow,  CB  cord  blood,  CNS  central  nervous  
system,  CR  complete   remission,  haplo  haploidentical,  HSCT  hematopoietic  stem  cell   transplantation,  MFD  
21	  
	  
matched  family  donor,  MUD  matched  unrelated  donor,  n  number,  PB  peripheral  blood,  PBSC  peripheral  blood  
stem  cells,  pts  patients,  TBI  total  body  irradiation.     
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Conditioning	  Regimen	   number	  of	  patients	  (%)	  
Cyclo+Thiotepa+	  TBI	   52	  (18.5%)	  
Ara-­‐c+TBI	   44	  (15.7%)	  
Thiotepa+Cyclo+ATG+TBI	   24	  (8.5%)	  
Etoposide+TBI	   18	  (6.4%)	  
Vincristine+Cyclo+TBI	   18	  (6.4%)	  
Etoposide+Cyclo+TBI	   14	  (5.0%)	  
Thiotepa+Fludara+TBI	   13	  (4.6%)	  
Cyclo+TBI	   10	  (3.6%)	  
Thiotepa+L-­‐Pam+TBI	   10	  (3.6%)	  
others+TBI	   36	  (12.8%)	  
NON	  TBI	   42	  (14.9%)	  
Bus+Thiotepa+Cyclo	   10	  
Bus+Cyclo	   5	  
Bus+Thiotepa+Fludara	   4	  
Other	   23	  
	  
Table  2:  Conditioning  regimens.  	  
Abbreviations:  Ara-­C  Cytarabine,  ATG  anti-­thymocyte  globulin,  Bus  Busulphan,  Cyclo  Cyclophosphamide,  
Fludara  Fludarabine,  L-­Pam  Melphalan,  TBI  total  body  irradiation       
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Age	   <  10  yrs	  







0.50	   -­	     



















0.42	   -­	     




















0.21	   0.86	     








0.0064	   0.0035	   0.5  (0.3-­0.8)	  








0.63	   -­	     








<0.0001	   0.0005	   2.3  (1.4-­30.7)	  
	  
Table  3:  Multivariable  analysis  of  factors  influencing  outcome  in  children  with  isolated  
extramedullary  relapse  of  ALL.	  
Abbreviations:  Bcp  B  cell  precursor,  CI  Confidence  Interval,  CNS  central  nervous  system,  CR  complete  
remission,  HSCT  hematopoietic  stem  cell  transplantation,  n  number,  OS  overall  survival,  Pts  patients,  TBI  
total  body  irradiation,  yrs  years.  	  
  




Figure  1:  Overall  survival  of  patients  transplanted  for  extramedullary  relapse  of  ALL  according  to  
the  type  of  HSCT  employed.	  
Abbreviations:  ALL  acute  lymphoblastic  leukemia,  auto  autologous  hematopoietic  stem  cell  
transplantation,  haplo  HLA-­haploidentical  donor,  HSCT  hematopoietic  stem  cell  transplantation,    
MFD  matched  family  donor,  MUD  matched  unrelated  donor.  
	  
Figure  2:  Overall  survival  of  patients  transplanted  for  extramedullary  relapse  of  ALL:  stratification  
per  remission  status  at  HSCT	  
Abbreviations:  ALL  acute  lymphoblastic  leukemia,  CR  complete  remission,  HSCT  hematopoietic  
stem  cell  transplantation.    
	  
Figure  3:  Overall  survival  of  patients  with  very  early  (A),  early  (B)  and  late  (C)  isolated  
extramedullary  ALL  relapse:  auto-­HSCT  versus  allo-­HSCT  (MFD,  MUD  and  haplo-­HSCT  
combined).	  
Abbreviations:  ALL  acute  lymphoblastic  leukemia,  allo-­HSCT  allogeneic  hematopoietic  stem  cell  
transplantation,  auto-­HSCT  autologous  hematopoietic  stem  cell  transplantation,  haplo  HLA-­
haploidentical  donor,  MFD  matched  family  donor,  MUD  matched  unrelated  donor.	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